Article Text
Abstract
Introduction The Solitaire stent retriever registry showed improved reperfusion, faster procedure times, and better outcome in acute stroke patients with large vessel occlusion treated with a balloon guide catheter (BGC) and Solitaire stent retriever compared with a conventional guide catheter. The goal of this study was to evaluate whether use of a BGC with the Trevo stent retriever improves outcomes compared with a conventional guide catheter.
Methods The TRACK registry recruited 23 sites to submit demographic, clinical, and site adjudicated angiographic and outcome data on consecutive patients treated with the Trevo stent retriever. BGC use was at the discretion of the physician.
Results 536 anterior circulation patients (of whom 279 (52.1%) had BGC placement) were included in this analysis. Baseline characteristics were notable for younger patients in the BGC group (65.4±15.3 vs 68.1±13.6, P=0.03) and lower rate of hypertension (72% vs 79%, P=0.06). Mean time from symptom onset to groin puncture was longer in the BGC group (357 vs 319 min, P=0.06).Thrombolysis in Cerebral Infarction 2b/3 scores were higher in the BGC cohort (84% vs 75.5%, P=0.01). There was no difference in reperfusion time, first pass effect, number of passes, or rescue therapy. Good clinical outcome at 3 months was superior in patients with BGC (57% vs 40%; P=0.0004) with a lower mortality rate (13% vs 23%, P=0.008). Multivariate analysis demonstrated that BGC use was an independent predictor of good clinical outcome (OR 2; 95% CI 1.3 to 3.1, P=0.001).
Conclusions In acute stroke patients presenting with anterior circulation large vessel occlusion, use of a BGC with the Trevo stent retriever resulted in improved reperfusion, improved clinical outcome, and lower mortality.
- stroke
- thrombectomy
- technique
- balloon
- catheter
Statistics from Altmetric.com
Footnotes
Contributors OOZ and ACC initiated and led the TRACK registry, and performed the data analysis. TNN drafted the manuscript and its revisions. All authors contributed data and revised the manuscript.
Funding Stryker Neurovascular; limited coordinating center administrative grant. Subanalysis supported by a SVIN pilot grant.
Competing interests TNN is a consultant for Medtronic. OOZ is a consultant/advisory board member for Stryker Neurovascular and Covidien. OOZ is overall principal investigator for TRACK–no compensation and Arise II–modest. RGN is a consultant/advisory board member for Stryker Neurovascular and Covidien. Stryker Neurovascular (Trevo-2 trial principal investigator–modest; DAWN trial principal investigator–no compensation, TREVO registry steering committee–no compensation), Medtronic (SWIFT trial steering committee–modest; SWIFT-Prime trial steering committee–no compensation; STAR Trial Angiographic Core Lab–significant), Penumbra (3D Separator trial executive committee–no compensation), Neuravi (ARISE-2 steering committee–no compensation), Genentech (physician advisory board–modest), Allm Inc (physician advisory board–no compensation), editor- in-chief Interventional Neurology journal (no compensation). SRS is a consultant for Stryker Neurovascular. JDE is a consultant for Stryker Neurovascular.
IL is a consultant for Medtronic, Stryker, Penumbra, and Cordis.Patient consent Not required.
Ethics approval Institutional review board approval was obtained from each institution’s review board
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement The data are only available to the coordinating investigators in the study.